Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | APOE-targeted epigenome therapy for Alzheimer’s disease

Ornit Chiba-Falek, PhD, Duke University School of Medicine, Durham, NC, shares insights into a novel epigenome therapy under investigation for the treatment of late onset Alzheimer’s disease (LOAD), that reduces APOE expression generally and the APOEe4 allele specifically. The therapy uses CRISPR/dCas9 gene editing technology designed to target regulatory elements within the APOE promoter/intron 1 region and the exon 4 sequence overlapping the SNP that defines the APOEe4 allele. It was then evaluated in vitro using human hiPSC-derived neurons and in vivo in mice brains using a dCas9-repressor vector and the GFP reporter gene. In vitro, APOE-mRNA and protein overall levels were reduced in hiPSC-derived neurons with the e4 allele while there was no effect in isogenic hiPSC-derived neurons homozygous for the e3 allele. In the mice, there was a 50-70% decrease in GFP expression, representing promising preliminary data for this APOE-targeted epigenome therapy. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Prof. Chiba-Falek reports the following disclosures:
-Co-Founder at CLAIRIgene
-CLAIRIgene is negotiating the licensing of the technology developed in this study